ES493152A0 - Un procedimiento para la preparacion de una composicion farmaceutica de cesion sostenida de un producto medio solido. - Google Patents

Un procedimiento para la preparacion de una composicion farmaceutica de cesion sostenida de un producto medio solido.

Info

Publication number
ES493152A0
ES493152A0 ES493152A ES493152A ES493152A0 ES 493152 A0 ES493152 A0 ES 493152A0 ES 493152 A ES493152 A ES 493152A ES 493152 A ES493152 A ES 493152A ES 493152 A0 ES493152 A0 ES 493152A0
Authority
ES
Spain
Prior art keywords
sustained
assignment
procedure
preparation
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES493152A
Other languages
English (en)
Other versions
ES8200557A1 (es
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yamanouchi Pharmaceutical Co Ltd
Original Assignee
Yamanouchi Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP8520979A external-priority patent/JPS5649314A/ja
Priority claimed from JP3651480A external-priority patent/JPS5948810B2/ja
Application filed by Yamanouchi Pharmaceutical Co Ltd filed Critical Yamanouchi Pharmaceutical Co Ltd
Publication of ES8200557A1 publication Critical patent/ES8200557A1/es
Publication of ES493152A0 publication Critical patent/ES493152A0/es
Granted legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ES493152A 1979-07-05 1980-07-04 Un procedimiento para la preparacion de una composicion farmaceutica de cesion sostenida de un producto medio solido. Granted ES493152A0 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP8520979A JPS5649314A (en) 1979-07-05 1979-07-05 Lasting pharmaceutical composition having prolonged action and its preparation
JP3651480A JPS5948810B2 (ja) 1980-03-22 1980-03-22 ニカルジピン持続性製剤用組成物

Publications (2)

Publication Number Publication Date
ES8200557A1 ES8200557A1 (es) 1981-11-16
ES493152A0 true ES493152A0 (es) 1981-11-16

Family

ID=26375569

Family Applications (1)

Application Number Title Priority Date Filing Date
ES493152A Granted ES493152A0 (es) 1979-07-05 1980-07-04 Un procedimiento para la preparacion de una composicion farmaceutica de cesion sostenida de un producto medio solido.

Country Status (9)

Country Link
US (3) US4343789A (es)
CA (1) CA1146866A (es)
CH (1) CH648484A5 (es)
DE (1) DE3024858C2 (es)
ES (1) ES493152A0 (es)
FR (1) FR2460667A1 (es)
GB (1) GB2053681B (es)
IT (1) IT1132169B (es)
SE (1) SE448342B (es)

Families Citing this family (297)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1146866A (en) * 1979-07-05 1983-05-24 Yamanouchi Pharmaceutical Co. Ltd. Process for the production of sustained release pharmaceutical composition of solid medical material
DE3033919A1 (de) * 1980-09-09 1982-04-22 Bayer Ag, 5090 Leverkusen Feste arzneizubereitungen enthaltend nifedipin und verfahren zu ihrer herstellung
JPS5846019A (ja) * 1981-09-14 1983-03-17 Kanebo Ltd 持続性ニフエジピン製剤
MX7567E (es) * 1981-12-23 1989-10-27 Yamanouchi Pharma Co Ltd Procedimiento para recubrir nicardipina de accion prolongada
JPS58116414A (ja) * 1981-12-23 1983-07-11 Yamanouchi Pharmaceut Co Ltd ニカルジピン持続性製剤用球形顆粒およびその製造法
US4758437A (en) * 1981-12-23 1988-07-19 Yamanouchi Pharmaceutical Co., Ltd. Composition for long acting nicardipine preparation and process of producing the composition
US4525345A (en) * 1981-12-24 1985-06-25 Verex Laboratories, Inc. Constant order release, solid dosage indomethacin formulation and method of treating arthritis and other inflammatory conditions
FR2525108B1 (fr) * 1982-04-19 1989-05-12 Elan Corp Ltd Medicaments a haut degre de solubilite et procede pour leur obtention
JPS597163A (ja) * 1982-07-02 1984-01-14 Yamanouchi Pharmaceut Co Ltd 抗動脈硬化剤
US4522956A (en) * 1982-07-29 1985-06-11 Richardson-Vicks Inc. Poly(ethylene oxide)/polyethylene glycol-containing hydrophilic denture adhesive
US4704284A (en) * 1982-08-12 1987-11-03 Pfizer Inc. Long-acting matrix tablet formulations
JPS59101423A (ja) * 1982-12-02 1984-06-12 Takada Seiyaku Kk 新規なニフエジピン固形製剤
US4851231A (en) * 1982-12-13 1989-07-25 Alza Corporation System for delivering drug in selected environment of use
US4721613A (en) * 1982-12-13 1988-01-26 Alza Corporation Delivery system comprising means for shielding a multiplicity of reservoirs in selected environment of use
DE3314003A1 (de) * 1983-04-18 1984-10-18 Boehringer Ingelheim KG, 6507 Ingelheim Teilbare tablette mit verzoegerter wirkstofffreigabe und verfahren zu deren herstellung
DE3318649A1 (de) * 1983-05-21 1984-11-22 Bayer Ag, 5090 Leverkusen Zweiphasenformulierung
US4777048A (en) * 1983-07-07 1988-10-11 American Home Products Corporation Pharmaceutical composition containing a liquid lubricant
US4832952A (en) * 1983-07-07 1989-05-23 American Home Products Corporation Pharmaceutical composition containing a liquid lubricant
US4620974A (en) * 1983-07-07 1986-11-04 American Home Products Corporation Pharmaceutical composition containing a liquid lubricant
JPS6038322A (ja) * 1983-08-11 1985-02-27 Fujisawa Pharmaceut Co Ltd ジヒドロピリジンａ物質含有易溶性固形製剤
ZA836030B (en) * 1983-08-16 1985-02-27 Verex Lab Constant order release solid dosage indomethacin formulation and method of treating arthritis and other inflammatory conditions
US4680323A (en) * 1983-12-01 1987-07-14 Hans Lowey Method and composition for the preparation of controlled long-acting pharmaceuticals for oral administration
US4610868A (en) * 1984-03-20 1986-09-09 The Liposome Company, Inc. Lipid matrix carriers for use in drug delivery systems
US4795327A (en) * 1984-03-26 1989-01-03 Forest Laboratories, Inc. Controlled release solid drug dosage forms based on mixtures of water soluble nonionic cellulose ethers and anionic surfactants
US4849229A (en) * 1984-03-26 1989-07-18 Forest Laboratories, Inc. Controlled release solid drug dosage forms based on mixtures of water soluble nonionic cellulose ethers and anionic surfactants
DE3580384D1 (de) * 1984-04-09 1990-12-13 Toyo Boseki Praeparat mit verzoegerter freigabe zum aufbringen auf die schleimhaeute der mundhoehle.
US4753652A (en) * 1984-05-04 1988-06-28 Children's Medical Center Corporation Biomaterial implants which resist calcification
JPS6124516A (ja) * 1984-07-12 1986-02-03 Fujisawa Pharmaceut Co Ltd 持続性錠剤
US4863744A (en) * 1984-09-17 1989-09-05 Alza Corporation Intestine drug delivery
US5474980A (en) * 1984-10-04 1995-12-12 Monsanto Company Prolonged release of biologically active somatotropins
US5411951A (en) * 1984-10-04 1995-05-02 Monsanto Company Prolonged release of biologically active somatotropin
ES8702440A1 (es) * 1984-10-04 1986-12-16 Monsanto Co Un procedimiento para la preparacion de una composicion de polipeptido inyectable sustancialmente no acuosa.
US5086041A (en) * 1984-10-04 1992-02-04 Monsanto Company Methods of using prolonged release somatotropin compositions
DE3438830A1 (de) * 1984-10-23 1986-04-30 Rentschler Arzneimittel Nifedipin enthaltende darreichungsform und verfahren zu ihrer herstellung
EP0187703B1 (en) * 1985-01-11 1992-08-05 Teijin Limited Sustained release preparation
GB8507779D0 (en) * 1985-03-26 1985-05-01 Fujisawa Pharmaceutical Co Drug carrier
US4720384A (en) * 1985-05-03 1988-01-19 E. I. Du Pont De Nemours And Company Manufacture of hollow fine tubular drug delivery systems
HU197201B (en) * 1985-10-01 1989-03-28 Sandoz Ag Process for producing oral pharmaceutical compositions of controlled solubility of the active components
IT1187751B (it) * 1985-10-15 1987-12-23 Eurand Spa Procedimento per la preparazione di formulazioni solidi di nifedipina ad elevata biodisponibilita' e ad effetto prolungato e formulazioni cosi' ottenute
JPS62103012A (ja) * 1985-10-23 1987-05-13 Eisai Co Ltd 多重顆粒
US5198226A (en) * 1986-01-30 1993-03-30 Syntex (U.S.A.) Inc. Long acting nicardipine hydrochloride formulation
US4940556A (en) * 1986-01-30 1990-07-10 Syntex (U.S.A.) Inc. Method of preparing long acting formulation
SE457326B (sv) * 1986-02-14 1988-12-19 Lejus Medical Ab Foerfarande foer framstaellning av en snabbt soenderfallande kaerna innehaallande bl a mikrokristallin cellulosa
GB8608080D0 (en) * 1986-04-02 1986-05-08 Fujisawa Pharmaceutical Co Solid dispersion composition
SE8601624D0 (sv) * 1986-04-11 1986-04-11 Haessle Ab New pharmaceutical preparations
US4816568A (en) * 1986-05-16 1989-03-28 International Minerals & Chemical Corp. Stabilization of growth hormones
US4772473A (en) * 1986-06-16 1988-09-20 Norwich Eaton Pharmaceuticals, Inc. Nitrofurantoin dosage form
US4798725A (en) * 1986-06-16 1989-01-17 Norwich Eaton Pharmaceuticals, Inc. Sustained release capsule
GB8618811D0 (en) * 1986-08-01 1986-09-10 Approved Prescription Services Sustained release ibuprofen formulation
US5035891A (en) * 1987-10-05 1991-07-30 Syntex (U.S.A.) Inc. Controlled release subcutaneous implant
SE8703881D0 (sv) * 1987-10-08 1987-10-08 Haessle Ab New pharmaceutical preparation
JP2643222B2 (ja) * 1988-02-03 1997-08-20 エーザイ株式会社 多重層顆粒
EP0406315B1 (en) * 1988-03-24 1992-11-11 Bukh Meditec A/S Controlled release composition
HU203041B (en) * 1989-03-14 1991-05-28 Egyt Gyogyszervegyeszeti Gyar Process for producing pharmaceutical compositions of controlled releasing factor containing nifedipin
US5158761A (en) * 1989-04-05 1992-10-27 Toko Yakuhin Kogyo Kabushiki Kaisha Spray gel base and spray gel preparation using thereof
US5215739A (en) * 1989-04-05 1993-06-01 Toko Yakuhin Kogyo Kabushiki Kaisha Spray gel base and spray gel preparation using thereof
DK469989D0 (da) * 1989-09-22 1989-09-22 Bukh Meditec Farmaceutisk praeparat
US5188837A (en) * 1989-11-13 1993-02-23 Nova Pharmaceutical Corporation Lipsopheres for controlled delivery of substances
US5227165A (en) * 1989-11-13 1993-07-13 Nova Pharmaceutical Corporation Liposphere delivery systems for local anesthetics
IE904098A1 (en) * 1989-11-13 1991-05-22 Nova Pharm Corp Lipospheres for controlled delivery of substances
US5221535A (en) * 1989-11-13 1993-06-22 Nova Pharmaceutical Corporation Sustained release formulations of insect repellent
US5209933A (en) * 1990-01-10 1993-05-11 Syntex (U.S.A.) Inc. Long acting calcium channel blocker composition
US5211959A (en) * 1990-01-11 1993-05-18 Japan Atomic Energy Research Institute Processes for producing slow-release powders
JPH03232817A (ja) * 1990-02-07 1991-10-16 Showa Yakuhin Kako Kk 貼付剤
US5316773A (en) * 1990-07-19 1994-05-31 Otsuka Pharmaceutical Co., Ltd. Particulate preparation containing a flourracil derivative and hydroxypropylmethyl-cellulose
IT1246188B (it) * 1990-07-27 1994-11-16 Resa Farma Procedimento per la preparazione di composizioni farmaceutiche aventi aumentata velocita' di dissoluzione della sostanza attiva e composizioni ottenute.
US5273758A (en) * 1991-03-18 1993-12-28 Sandoz Ltd. Directly compressible polyethylene oxide vehicle for preparing therapeutic dosage forms
TW212139B (es) * 1991-04-15 1993-09-01 Yamanouchi Pharma Co Ltd
TW209174B (es) * 1991-04-19 1993-07-11 Takeda Pharm Industry Co Ltd
US5968551A (en) 1991-12-24 1999-10-19 Purdue Pharma L.P. Orally administrable opioid formulations having extended duration of effect
GB9200607D0 (en) * 1992-01-13 1992-03-11 Ethical Pharma Ltd Pharmaceutical compositions containing nifedipine and process for the preparation thereof
US5286495A (en) * 1992-05-11 1994-02-15 University Of Florida Process for microencapsulating cells
US5922340A (en) 1992-09-10 1999-07-13 Children's Medical Center Corporation High load formulations and methods for providing prolonged local anesthesia
HU226456B1 (en) 1992-09-18 2008-12-29 Astellas Pharma Inc Sustained-release hydrogel preparation
US6024090A (en) * 1993-01-29 2000-02-15 Aradigm Corporation Method of treating a diabetic patient by aerosolized administration of insulin lispro
IL109460A (en) * 1993-05-10 1998-03-10 Euro Celtique Sa Controlled release formulation comprising tramadol
IL110014A (en) 1993-07-01 1999-11-30 Euro Celtique Sa Solid controlled-release oral dosage forms of opioid analgesics
US7740881B1 (en) 1993-07-01 2010-06-22 Purdue Pharma Lp Method of treating humans with opioid formulations having extended controlled release
US5879705A (en) 1993-07-27 1999-03-09 Euro-Celtique S.A. Sustained release compositions of morphine and a method of preparing pharmaceutical compositions
US5455046A (en) * 1993-09-09 1995-10-03 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems for insoluble drugs
US5662933A (en) * 1993-09-09 1997-09-02 Edward Mendell Co., Inc. Controlled release formulation (albuterol)
US5773025A (en) * 1993-09-09 1998-06-30 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems--amorphous drugs
US6726930B1 (en) * 1993-09-09 2004-04-27 Penwest Pharmaceuticals Co. Sustained release heterodisperse hydrogel systems for insoluble drugs
RO115412B1 (ro) * 1993-10-01 2000-02-28 Syntex Inc Compozitie farmaceutica si procedeu de obtinere a compozitiei farmaceutice
KR100354702B1 (ko) * 1993-11-23 2002-12-28 유로-셀티크 소시에떼 아노뉨 약학조성물의제조방법및서방형조성물
US5891471A (en) * 1993-11-23 1999-04-06 Euro-Celtique, S.A. Pharmaceutical multiparticulates
US5843480A (en) * 1994-03-14 1998-12-01 Euro-Celtique, S.A. Controlled release diamorphine formulation
GB9422154D0 (en) * 1994-11-03 1994-12-21 Euro Celtique Sa Pharmaceutical compositions and method of producing the same
US5965161A (en) 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
NZ270439A (en) * 1995-02-02 1996-04-26 Bernard Charles Sherman Solid slow release pharmaceutical composition: carrier is polyethylene glycol and hydrophilic gel-forming polymer
US6348469B1 (en) 1995-04-14 2002-02-19 Pharma Pass Llc Solid compositions containing glipizide and polyethylene oxide
US20040018236A1 (en) * 1995-05-08 2004-01-29 Robert Gurny Nanoparticles for oral administration of pharmaceutical agents of low solubility
AU706541B2 (en) 1995-06-09 1999-06-17 Euro-Celtique S.A. Formulations and methods for providing prolonged local anesthesia
TW487582B (en) * 1995-08-11 2002-05-21 Nissan Chemical Ind Ltd Method for converting sparingly water-soluble medical substance to amorphous state
NZ286451A (en) * 1996-04-24 1998-04-27 Bernard Charles Sherman Controlled release pharmaceutical composition containing granules comprising drug, water-insoluble polymer and meltable carrier
US5855615A (en) * 1996-06-07 1999-01-05 Menlo Care, Inc. Controller expansion sphincter augmentation media
WO1997049391A1 (en) 1996-06-24 1997-12-31 Euro-Celtique, S.A. Methods for providing safe local anesthesia
EP0859603B1 (en) 1996-07-08 2008-12-17 Penwest Pharmaceuticals Co. Sustained release matrix for high-dose insoluble drugs
US7049346B1 (en) * 1996-08-20 2006-05-23 Menlo Care Div Of Ethicon, Inc. Swollen hydrogel for sphincter augmentation
US5813411A (en) * 1996-08-20 1998-09-29 Menlo Care, Inc. Method of deforming tissue with a swollen hydrogel
US6046187A (en) * 1996-09-16 2000-04-04 Children's Medical Center Corporation Formulations and methods for providing prolonged local anesthesia
US5972389A (en) * 1996-09-19 1999-10-26 Depomed, Inc. Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter
TW486370B (en) * 1996-12-25 2002-05-11 Yamanouchi Pharma Co Ltd Rapidly disintegrable pharmaceutical composition
BR9815499A (pt) 1997-07-02 2001-01-02 Euro Celtique Sa Anestesia prolongada nas juntas e nos espacos corporais.
JP2001527023A (ja) * 1997-08-11 2001-12-25 アルザ・コーポレーション 胃で保持するのに適合した長期放出性活性剤剤形
IN186245B (es) 1997-09-19 2001-07-14 Ranbaxy Lab Ltd
US6056977A (en) 1997-10-15 2000-05-02 Edward Mendell Co., Inc. Once-a-day controlled release sulfonylurea formulation
HUP0004345A3 (en) * 1997-11-12 2001-10-29 Boehringer Mannheim Pharm Corp Novel oral pharmaceutical compositions containing from carvedilol
US6099859A (en) * 1998-03-20 2000-08-08 Andrx Pharmaceuticals, Inc. Controlled release oral tablet having a unitary core
HUP9902351A3 (en) * 1998-07-22 2001-01-29 Pharma Pass L L C Irvine Solid compositions containing metoprolol and process for producing the same
EP0974343B1 (en) * 1998-07-22 2004-09-29 Pharma Pass II LLC Process for manufacturing a solid metoprolol composition
EP0987020A1 (en) * 1998-09-04 2000-03-22 Pharma Pass LLC Metoprolol composition and processes for manufacturing the same
US6806294B2 (en) 1998-10-15 2004-10-19 Euro-Celtique S.A. Opioid analgesic
US6238697B1 (en) 1998-12-21 2001-05-29 Pharmalogix, Inc. Methods and formulations for making bupropion hydrochloride tablets using direct compression
ATE400252T1 (de) 1999-02-10 2008-07-15 Pfizer Prod Inc Pharmazeutische feste dispersionen
DE19918325A1 (de) 1999-04-22 2000-10-26 Euro Celtique Sa Verfahren zur Herstellung von Arzneiformen mit regulierter Wirkstofffreisetzung mittels Extrusion
GB2381453A (en) * 1999-08-31 2003-05-07 Bradford Particle Design Ltd Active/polymer coformulations
GB9920558D0 (en) * 1999-08-31 1999-11-03 Bradford Particle Design Ltd Methods for particle formation and their products
AU762291B2 (en) * 1999-09-30 2003-06-19 Penwest Pharmaceutical Co. Sustained release matrix systems for highly soluble drugs
EP2295043A1 (en) 1999-10-29 2011-03-16 Euro-Celtique S.A. Controlled release hydrocodone formulations
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
ATE329579T1 (de) 1999-11-12 2006-07-15 Abbott Lab Feste dispersion mit ritonavir, fenofibrat oder griseofulvin
MXPA02006324A (es) 1999-12-23 2002-12-13 Pfizer Prod Inc Composiciones farmaceuticas que proporcionan concentraciones potenciadas de farmaco.
US20020028240A1 (en) * 2000-04-17 2002-03-07 Toyohiro Sawada Timed-release compression-coated solid composition for oral administration
US6419954B1 (en) 2000-05-19 2002-07-16 Yamanouchi Pharmaceutical Co., Ltd. Tablets and methods for modified release of hydrophilic and other active agents
US6423332B1 (en) 2000-05-26 2002-07-23 Ethicon, Inc. Method and composition for deforming soft tissues
DE10026698A1 (de) 2000-05-30 2001-12-06 Basf Ag Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
EP2932964A1 (en) 2000-10-30 2015-10-21 Euro-Celtique S.A. Controlled release hydrocodone formulations
WO2002087588A1 (fr) * 2001-04-26 2002-11-07 Meiji Seika Kaisha, Ltd. Composition de cefditoren pivoxil amorphe et procede de fabrication correspondant
US20110104214A1 (en) 2004-04-15 2011-05-05 Purdue Pharma L.P. Once-a-day oxycodone formulations
UA81224C2 (uk) 2001-05-02 2007-12-25 Euro Celtic S A Дозована форма оксикодону та її застосування
US6524618B1 (en) 2001-06-12 2003-02-25 Vijai Kumar Directly compressible extended-release matrix formulation for metformin hydrochloride
CA2450957A1 (en) * 2001-06-22 2003-01-03 Pfizer Products Inc. Pharmaceutical compositions of dispersions of drugs and neutral polymers
SK15742003A3 (sk) * 2001-06-22 2005-01-03 Pfizer Products Inc. Farmaceutická kompozícia zahrnujúca adsorbát amorfného liečiva
DK1411899T3 (da) * 2001-08-01 2009-06-02 Novartis Ag Smagsmaskerende sammensætning
US20030068375A1 (en) 2001-08-06 2003-04-10 Curtis Wright Pharmaceutical formulation containing gelling agent
US20040253310A1 (en) 2001-09-21 2004-12-16 Gina Fischer Morphine polymer release system
WO2003024429A1 (en) * 2001-09-21 2003-03-27 Egalet A/S Polymer release system
US7612112B2 (en) 2001-10-25 2009-11-03 Depomed, Inc. Methods of treatment using a gastric retained gabapentin dosage
US6723340B2 (en) 2001-10-25 2004-04-20 Depomed, Inc. Optimal polymer mixtures for gastric retentive tablets
TWI312285B (en) 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
US20060159743A1 (en) * 2001-10-25 2006-07-20 Depomed, Inc. Methods of treating non-nociceptive pain states with gastric retentive gabapentin
WO2003063868A1 (en) 2002-02-01 2003-08-07 Pfizer Products Inc. Controlled release pharmaceutical dosage forms of a cholesteryl ester transfer protein inhibitor
AR038375A1 (es) 2002-02-01 2005-01-12 Pfizer Prod Inc Composiciones farmaceuticas de inhibidores de la proteina de transferencia de esteres de colesterilo
EP1920766B1 (en) 2002-02-01 2017-08-23 Bend Research, Inc Pharmaceutical compositions of amorphous dispersions of drugs and lipophilic microphase-forming materials
WO2003063833A1 (en) * 2002-02-01 2003-08-07 Pfizer Products Inc. Pharmaceutical compositions of amorphous dispersions of drugs and lipophilic microphase-forming materials
ITMI20021074A1 (it) * 2002-05-20 2003-11-20 Actimex S R L Composizione ternaria comprendente una sostanza attiva e processo di comacinazione per la sua preparazione
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
EP2111856A3 (en) 2002-08-12 2014-09-10 Bend Research, Inc. Pharmaceutical compositions of semi-ordered drugs and polymers
AU2003291757A1 (en) * 2002-11-08 2004-06-03 Bristol-Myers Squibb Company Formulations of low solubility bioactive agents and processes for making the same
DE60323536D1 (de) 2002-12-20 2008-10-23 Pfizer Prod Inc Dosierungsform enthaltend einen cetp-hemmer und einen hmg-coa reduktase hemmer
US7442387B2 (en) * 2003-03-06 2008-10-28 Astellas Pharma Inc. Pharmaceutical composition for controlled release of active substances and manufacturing method thereof
ATE495732T1 (de) 2003-03-26 2011-02-15 Egalet As Morphin-system mit kontrollierter freisetzung
US20050042289A1 (en) * 2003-04-29 2005-02-24 Yamanouchi Pharma Technologies, Inc. Tablets and methods for modified release of hydrophylic and other active agents
US7135436B2 (en) * 2003-05-05 2006-11-14 J.F. Daley International, Ltd. Solid algicide, preparation and usage in recirculating water
JP2007501218A (ja) 2003-08-04 2007-01-25 ファイザー・プロダクツ・インク 非晶質薬物の吸着物および親油性ミクロ相形成物質の医薬組成物
US8075872B2 (en) 2003-08-06 2011-12-13 Gruenenthal Gmbh Abuse-proofed dosage form
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
DE10361596A1 (de) 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
DE102004032051A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten, festen Darreichungsform
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
US8377952B2 (en) 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
EP1696887A1 (en) * 2003-11-14 2006-09-06 Pfizer Products Inc. Solid amorphous dispersions of an mtp inhibitor for treatment of obesity
JP2007513937A (ja) * 2003-12-09 2007-05-31 ファイザー インコーポレイテッド Ｈｉｖプロテアーゼ阻害剤を含む組成物
US7507823B2 (en) * 2004-05-06 2009-03-24 Bristol-Myers Squibb Company Process of making aripiprazole particles
WO2005116034A1 (en) 2004-05-25 2005-12-08 Pfizer Products Inc. Tetraazabenzo[e]azulene derivatives and analogs thereof
DE102004032049A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
WO2006082518A1 (en) 2005-02-03 2006-08-10 Pfizer Products Inc. Pharmaceutical compositions with enhanced performance
DE102005005449A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
KR100691608B1 (ko) * 2005-02-21 2007-03-12 (주)나노하이브리드 염기성 고분자가 첨가된 유리 염기형 약물과 층상형 규산염의 하이브리드 및 그의 제조방법
JP5161075B2 (ja) * 2005-06-03 2013-03-13 エガレット エイ／エス 分散媒体の第１フラクションとマトリックスの第２フラクションを有し、第２フラクションが胃腸の液体に少なくとも部分的に最初に曝される固形の医薬組成物
RU2408368C2 (ru) 2005-06-27 2011-01-10 Биовэйл Лэборэториз Интернэшнл С.Р.Л. Препараты соли бупропиона с модифицированным высвобождением
US8778395B2 (en) 2005-08-11 2014-07-15 Andrx Labs, Llc Diltiazem controlled release formulation and method of manufacture
MX2008006888A (es) 2005-11-28 2008-09-30 Marinus Pharmaceuticals Formulas y metodos para la manufactura y uso de la ganaxolona.
US20090176882A1 (en) * 2008-12-09 2009-07-09 Depomed, Inc. Gastric retentive gabapentin dosage forms and methods for using same
EP2020411A4 (en) 2006-05-23 2010-08-04 Mochida Pharm Co Ltd TETRACYCLIC SPIRO COMPOUND
US20080009502A1 (en) * 2006-07-07 2008-01-10 Access Business Group International Llc Tadalafil solid composites
CA2671200A1 (en) * 2006-07-21 2008-01-24 Lab International Srl Hydrophilic abuse deterrent delivery system
SA07280459B1 (ar) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
EP2081435B1 (en) 2006-09-22 2016-05-04 Pharmacyclics LLC Inhibitors of bruton's tyrosine kinase
US7638541B2 (en) 2006-12-28 2009-12-29 Metabolex Inc. 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
DE102007011485A1 (de) 2007-03-07 2008-09-11 Grünenthal GmbH Darreichungsform mit erschwertem Missbrauch
US20090148498A1 (en) * 2007-05-14 2009-06-11 Sustained Nano Systems Llc Controlled release implantable dispensing device and method
US20080292680A1 (en) * 2007-05-14 2008-11-27 Sustained Nano Systems Llc Hypercompressed polymer particles for controlled release ophthalmic medications
US8071119B2 (en) * 2007-05-14 2011-12-06 Sustained Nano Systems Llc Controlled release implantable dispensing device and method
WO2008148798A2 (en) 2007-06-04 2008-12-11 Egalet A/S Controlled release pharmaceutical compositions for prolonged effect
DE102007028869A1 (de) * 2007-06-22 2008-12-24 Ratiopharm Gmbh Verfahren zur Herstellung eines Arzneimittels enthaltend Tadalafil
WO2009014910A2 (en) 2007-07-19 2009-01-29 Metabolex, Inc. N-azacyclic substituted pyrrole, pyrazole, imidazole, triazole and tetrazole derivatives as agonists of the rup3 or gpr119 receptor for the treatment of diabetes and metabolic disorders
RU2465272C2 (ru) 2007-09-10 2012-10-27 КалсиМедика, Инк. Соединения, моделирующие внутриклеточный кальций
WO2009085637A1 (en) * 2007-12-21 2009-07-09 Url Pharma, Inc. Amorphous metaxalone and amorphous dispersions thereof
JP5774853B2 (ja) 2008-01-25 2015-09-09 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 医薬投薬形
US20090246276A1 (en) 2008-01-28 2009-10-01 Graham Jackson Pharmaceutical Compositions
EP2280704B1 (en) * 2008-03-31 2015-05-13 Cymabay Therapeutics, Inc. Oxymethylene aryl compounds and uses thereof
TWI524904B (zh) 2008-05-09 2016-03-11 歌林達股份有限公司 製備醫藥用固體劑型，尤指錠劑之方法，及製備固體劑型，尤指錠劑之前驅物之方法
AU2009288245B2 (en) 2008-08-27 2012-12-20 Calcimedica, Inc. Compounds that modulate intracellular calcium
CA2737543C (en) * 2008-09-19 2015-01-06 Activus Pharma Co., Ltd. Composite organic compound powder for medical use and production method and suspension of the same
US20110160222A1 (en) * 2008-11-26 2011-06-30 Metabolex, Inc. Modulators of glucose homeostasis for the treatment of diabetes and metabolic disorders
WO2010067233A1 (en) 2008-12-08 2010-06-17 Pfizer Inc. 1,2,4 triazolo [4, 3 -a] [1,5] benzodiazepin-5 (6h) -ones as agonists of the cholecystokinin-1 receptor (cck-ir)
CA2751667C (en) 2009-02-06 2016-12-13 Egalet Ltd. Immediate release composition resistant to abuse by intake of alcohol
RU2012101214A (ru) 2009-06-16 2013-07-27 Пфайзер Инк. Лекарственные формы апиксабана
AU2010265213B2 (en) 2009-06-24 2012-08-23 Egalet Ltd. Controlled release formulations
CA2765971C (en) 2009-07-22 2017-08-22 Gruenenthal Gmbh Hot-melt extruded controlled release dosage form
JP2012533586A (ja) 2009-07-22 2012-12-27 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 酸化安定化された不正使用防止剤形
CN102665413A (zh) * 2009-09-30 2012-09-12 微剂量治疗技术公司 治疗雷诺氏现象的方法和组合物
ES2497566T3 (es) 2009-10-01 2014-09-23 Cymabay Therapeutics, Inc. Sales de tetrazol-1-il-fenoximetil-tiazol-2-il-piperidinil-pirimidina sustituida
US7741330B1 (en) 2009-10-12 2010-06-22 Pharmacyclics, Inc. Pyrazolo-pyrimidine inhibitors of Bruton's tyrosine kinase
ES2606227T3 (es) 2010-02-03 2017-03-23 Grünenthal GmbH Preparación de una composición farmacéutica en polvo mediante una extrusora
US20130030237A1 (en) 2010-04-15 2013-01-31 Charles Theuer Potentiation of anti-cancer activity through combination therapy with ber pathway inhibitors
JP2013525448A (ja) 2010-04-27 2013-06-20 カルシメディカ，インク． 細胞内カルシウムを調節する化合物
PT2563776T (pt) 2010-04-27 2016-09-19 Calcimedica Inc Compostos que modulam o cálcio intracelular
EP2571860A1 (en) 2010-05-21 2013-03-27 Pfizer Inc 2-phenyl benzoylamides
WO2011163090A1 (en) 2010-06-23 2011-12-29 Metabolex, Inc. Compositions of 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
EP2609095A4 (en) 2010-08-27 2014-06-18 Calcimedica Inc COMPOUNDS MODULATING INTRACELLULAR CALCIUM
NZ608865A (en) 2010-09-02 2015-03-27 Gruenenthal Chemie Tamper resistant dosage form comprising an anionic polymer
AU2011297901B2 (en) 2010-09-02 2014-07-31 Grunenthal Gmbh Tamper resistant dosage form comprising inorganic salt
WO2012164575A2 (en) 2011-05-27 2012-12-06 Hetero Research Foundation Amorphous ritonavir co-precipitated
CN103841964A (zh) 2011-07-29 2014-06-04 格吕伦塔尔有限公司 提供药物立即释放的抗破碎片剂
PT2736497T (pt) 2011-07-29 2017-11-30 Gruenenthal Gmbh Comprimido resistente a adulteração proporcionando libertação imediata de fármaco
US20130143867A1 (en) 2011-12-02 2013-06-06 Sychroneuron Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same
US8377946B1 (en) 2011-12-30 2013-02-19 Pharmacyclics, Inc. Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
JP6117249B2 (ja) 2012-02-28 2017-04-19 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 薬理学的に活性な化合物および陰イオン性ポリマーを含むタンパーレジスタント剤形
WO2013156453A1 (en) 2012-04-18 2013-10-24 Grünenthal GmbH Tamper resistant and dose-dumping resistant pharmaceutical dosage form
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
WO2014059333A1 (en) 2012-10-12 2014-04-17 Calcimedica, Inc. Compounds that modulate intracellular calcium
CA2913209A1 (en) 2013-05-29 2014-12-04 Grunenthal Gmbh Tamper resistant dosage form with bimodal release profile
MX371432B (es) 2013-05-29 2020-01-30 Gruenenthal Gmbh Forma de dosificacion resistente al uso indebido que contiene una o mas particulas.
EP3878445A3 (en) 2013-06-05 2021-10-27 Synchroneuron Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same
MX368846B (es) 2013-07-12 2019-10-18 Gruenenthal Gmbh Forma de dosificación resistente a la alteración que contiene polímero de acetato de etilen-vinilo.
WO2015054283A1 (en) 2013-10-08 2015-04-16 Calcimedica, Inc. Compounds that modulate intracellular calcium
EP3073994A1 (en) 2013-11-26 2016-10-05 Grünenthal GmbH Preparation of a powdery pharmaceutical composition by means of cryo-milling
BR112016012728A2 (pt) 2013-12-05 2020-08-11 Pharmacyclics Llc compostos inibidores de tirosina quinase de bruton, composição farmacêutica os compreendendo e uso dos mesmos
HUE049323T2 (hu) 2014-02-10 2020-09-28 Respivant Sciences Gmbh Hízósejt-stabilizálók tüdõbetegség kezelésére
EP3104853B1 (en) 2014-02-10 2019-10-02 Respivant Sciences GmbH Mast cell stabilizers treatment for systemic disorders
SI3119757T1 (en) 2014-03-17 2018-08-31 Pfizer Inc. DIACILGLICEROL-ACILTRANSFERAZE 2 BINDERS FOR THE USE IN THE TREATMENT OF PRECIOUS AND RELATED DISEASES
EP3134418A4 (en) 2014-04-23 2018-01-03 The Research Foundation for The State University of New York A rapid and efficient bioorthogonal ligation reaction and boron-containing heterocycles useful in conjuction therewith
EP3142646A1 (en) 2014-05-12 2017-03-22 Grünenthal GmbH Tamper resistant immediate release capsule formulation comprising tapentadol
EA201692388A1 (ru) 2014-05-26 2017-05-31 Грюненталь Гмбх Лекарственная форма в виде множества частиц, защищенная от вызываемого этанолом сброса дозы
TW201613579A (en) 2014-06-24 2016-04-16 Astellas Pharma Inc Pharmaceutical composition for oral administration
US9839644B2 (en) 2014-09-09 2017-12-12 ARKAY Therapeutics, LLC Formulations and methods for treatment of metabolic syndrome
US9359316B1 (en) 2014-11-25 2016-06-07 Concentric Analgesics, Inc. Prodrugs of phenolic TRPV1 agonists
US10227333B2 (en) 2015-02-11 2019-03-12 Curtana Pharmaceuticals, Inc. Inhibition of OLIG2 activity
WO2016138479A1 (en) 2015-02-27 2016-09-01 Curtana Pharmaceuticals, Inc. Inhibition of olig2 activity
EA035434B1 (ru) 2015-04-24 2020-06-15 Грюненталь Гмбх Защищенная от применения не по назначению лекарственная форма с немедленным высвобождением и устойчивостью к экстракции растворителями
WO2017027402A1 (en) 2015-08-07 2017-02-16 Patara Pharma, LLC Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders
EP3331522A1 (en) 2015-08-07 2018-06-13 Patara Pharma LLC Methods for the treatment of mast cell related disorders with mast cell stabilizers
EP3346991A1 (en) 2015-09-10 2018-07-18 Grünenthal GmbH Protecting oral overdose with abuse deterrent immediate release formulations
US10851123B2 (en) 2016-02-23 2020-12-01 Concentric Analgesics, Inc. Prodrugs of phenolic TRPV1 agonists
CA3024556A1 (en) 2016-05-12 2017-11-16 The Regents Of The University Of Michigan Ash1l inhibitors and methods of treatment therewith
CA3025268A1 (en) 2016-05-25 2017-11-30 Concentric Analgesics, Inc. Prodrugs of phenolic trpv1 agonists in combination with local anesthetics and vasoconstrictors for improved local anesthesia
WO2017205769A1 (en) 2016-05-27 2017-11-30 Pharmacyclics Llc Inhibitors of interleukin-1 receptor-associated kinase
WO2017205766A1 (en) 2016-05-27 2017-11-30 Pharmacyclics Llc Inhibitors of interleukin-1 receptor-associated kinase
WO2017205762A1 (en) 2016-05-27 2017-11-30 Pharmacyclics Llc Inhibitors of interleukin-1 receptor-associated kinase
AU2017305392A1 (en) 2016-08-03 2019-02-21 Cymabay Therapeutics, Inc. Oxymethylene aryl compounds for treating inflammatory gastrointestinal diseases or gastrointestinal conditions
AR109179A1 (es) 2016-08-19 2018-11-07 Pfizer Inhibidores de diacilglicerol aciltransferasa 2
SG11201901679XA (en) 2016-08-26 2019-03-28 Curtana Pharmaceuticals Inc Inhibition of olig2 activity
WO2018044942A1 (en) 2016-08-31 2018-03-08 Patara Pharma, LLC Cromolyn compositions for treatment of chronic cough due to idiopathic pulmonary fibrosis
WO2018067341A1 (en) 2016-10-07 2018-04-12 Patara Pharma, LLC Cromolyn compositions for treatment of pulmonary fibrosis
BR112019018688A2 (pt) 2017-03-10 2020-04-07 Pfizer derivados de imidazo[4,5-c] quinolina como inibidores de lrrk2
EP3703724A1 (en) 2017-11-02 2020-09-09 NatureCeuticals Sdn. Bhd. Extract of orthosiphon stamineus, formulations, and uses thereof
EP3706867A4 (en) 2017-11-07 2021-08-11 The Regents Of The University Of Michigan THERAPEUTIC COMBINATION FOR TREATMENT OF CEREBELLIC ATAXIA
US11110177B2 (en) 2017-11-10 2021-09-07 The Regents Of The University Of Michigan ASH1L degraders and methods of treatment therewith
CA3084809A1 (en) 2017-12-07 2019-06-13 The Regents Of The University Of Michigan Nsd family inhibitors and methods of treatment therewith
WO2019169112A1 (en) 2018-02-28 2019-09-06 Curtana Pharmaceuticals, Inc. Inhibition of olig2 activity
CA3102777A1 (en) 2018-06-07 2019-12-12 The Regents Of The University Of Michigan Prc1 inhibitors and methods of treatment therewith
CA3107433A1 (en) 2018-07-27 2020-01-30 Concentric Analgesics, Inc. Pegylated prodrugs of phenolic trpv1 agonists
US20200069742A1 (en) 2018-08-29 2020-03-05 Myos Rens Technology Inc. Methods for alleviating, inhibiting or reversing muscle disuse atrophy in mammals
MX2021002428A (es) 2018-08-31 2023-01-02 Pfizer Combinaciones para tratamiento de ehna/ehgna y enfermedades relacionadas.
US20200108102A1 (en) 2018-10-03 2020-04-09 Myos Rens Technology Inc. Spray dried follistatin product
WO2020096660A1 (en) 2018-11-06 2020-05-14 Myos Rens Technology, Inc. Methods and compositions for improving skeletal muscle protein fractional synthetic rate
CA3125350A1 (en) 2018-12-31 2020-07-09 Biomea Fusion, Llc Irreversible inhibitors of menin-mll interaction
WO2020160113A1 (en) 2019-02-01 2020-08-06 Myos Rens Technology Inc. Egg yolk powder for improving quality of life and increasing activity in aging and chronically ill mammals
KR20220009373A (ko) 2019-03-15 2022-01-24 유니사이시브 테라퓨틱스 인코포레이티드 니코란딜 유도체
MX2021012491A (es) 2019-04-19 2022-01-24 Pfizer Agentes antiproliferativos para el tratamiento de la hipertensión arterial pulmonar.
EP3972596A1 (en) 2019-05-20 2022-03-30 Pfizer Inc. Combinations comprising benzodioxol as glp-1r agonists for use in the treatment of nash/nafld and related diseases
TW202115086A (zh) 2019-06-28 2021-04-16 美商輝瑞大藥廠 Bckdk抑制劑
US20220363673A1 (en) 2019-06-28 2022-11-17 Pfizer Inc. 5-(Thiophen-2-YL)-1 H-Tetrazole Derivative as BCKDK Inhibitors Useful for Treating Various Diseases
TWI771766B (zh) 2019-10-04 2022-07-21 美商輝瑞股份有限公司 二醯基甘油醯基轉移酶２ 抑制劑
JP2021134211A (ja) 2020-02-24 2021-09-13 ファイザー・インク Ｎａｆｌｄ／ｎａｓｈおよび関連疾患の処置のための組合せ
JP2022058085A (ja) 2020-02-24 2022-04-11 ファイザー・インク ジアシルグリセロールアシルトランスフェラーゼ２阻害剤とアセチル－ＣｏＡカルボキシラーゼ阻害剤との組合せ
JP7288554B1 (ja) 2020-06-09 2023-06-07 ファイザー・インク メラノコルチン４受容体アンタゴニストとしてのスピロ化合物およびそれらの使用
US11858925B2 (en) 2020-07-10 2024-01-02 The Regents Of The University Of Michigan GAS41 inhibitors and methods of use thereof
US20240124467A1 (en) 2020-12-16 2024-04-18 Biomea Fusion, Inc. Fused pyrimidine compounds as inhibitors of menin-mll interaction
CA3228627A1 (en) 2021-08-11 2023-02-16 Thomas Butler Covalent inhibitors of menin-mll interaction for diabetes mellitus
WO2023027966A1 (en) 2021-08-24 2023-03-02 Biomea Fusion, Inc. Pyrazine compounds as irreversible inhibitors of flt3
WO2023039240A1 (en) 2021-09-13 2023-03-16 Biomea Fusion, Inc. IRREVERSIBLE INHIBITORS OF KRas
WO2023086341A1 (en) 2021-11-09 2023-05-19 Biomea Fusion, Inc. Inhibitors of kras
WO2023100061A1 (en) 2021-12-01 2023-06-08 Pfizer Inc. 3-phenyl-1-benzothiophene-2-carboxylic acid derivatives as branched-chain alpha keto acid dehydrogenase kinase inhibitors for the treatment of diabetes, kidney diseases, nash and heart failure
WO2023105387A1 (en) 2021-12-06 2023-06-15 Pfizer Inc. Melanocortin 4 receptor antagonists and uses thereof
TW202340177A (zh) 2021-12-30 2023-10-16 美商拜歐米富士恩股份有限公司 作為 flt3抑制劑之吡嗪化合物
WO2023235618A1 (en) 2022-06-03 2023-12-07 Biomea Fusion, Inc. Fused pyrimidine compounds as inhibitors of menin
WO2024075051A1 (en) 2022-10-07 2024-04-11 Pfizer Inc. Hsd17b13 inhibitors and/or degraders
WO2024084360A1 (en) 2022-10-18 2024-04-25 Pfizer Inc. Patatin-like phospholipase domain-containing protein 3 (pnpla3) modifiers
WO2024084390A1 (en) 2022-10-18 2024-04-25 Pfizer Inc. Compounds for the activation of ampk
WO2024084363A1 (en) 2022-10-18 2024-04-25 Pfizer Inc. Use of patatin-like phospholipase domain-containing protein 3 compounds
WO2024086613A2 (en) 2022-10-19 2024-04-25 Myos Corp. Myogenic compounds

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL44885C (es) * 1935-11-09
US2540253A (en) * 1949-02-08 1951-02-06 Merck & Co Inc Granulation process
US2698822A (en) * 1951-04-28 1955-01-04 Fougera & Co Inc E Cardiac glycoside buccal composition
GB1050396A (es) * 1964-03-31
US3297804A (en) * 1964-05-19 1967-01-10 Ono Pharmaceutical Co Method of filling hard capsules with granules by the open-mouth-down punching method
US3308217A (en) * 1965-02-09 1967-03-07 Lowy Lawrence Method of granulating materials for subsequent forming into tablets
US4132753A (en) * 1965-02-12 1979-01-02 American Cyanamid Company Process for preparing oral sustained release granules
US3374146A (en) * 1966-04-18 1968-03-19 American Cyanamid Co Sustained release encapsulation
US3458622A (en) * 1967-04-07 1969-07-29 Squibb & Sons Inc Controlled release tablet
US3692896A (en) * 1968-06-14 1972-09-19 Isumura Juntendo Co Ltd Process for the preparation of water-soluble tablets
NL6808619A (es) * 1968-06-19 1969-12-23
US3634584A (en) * 1969-02-13 1972-01-11 American Home Prod Sustained action dosage form
US3852421A (en) * 1970-03-23 1974-12-03 Shinetsu Chemical Co Excipient and shaped medicaments prepared therewith
US3862311A (en) * 1971-04-12 1975-01-21 Ciba Geigy Corp Novel method of enhancing progestational endometrial proliferation with progesterone
DE2400819C2 (de) 1974-01-09 1982-04-22 Bayer Ag, 5090 Leverkusen Verfahren zur Herstellung fester Zubereitungen von schwerlöslichen Arzneimittelwirkstoffen in feinster Verteilung
US4086346A (en) * 1974-04-06 1978-04-25 Bayer Aktiengesellschaft Preparation of melt-sprayed spherical phenacetin granules
JPS5438167B2 (es) * 1974-04-27 1979-11-19
JPS517116A (en) * 1974-06-11 1976-01-21 Shinetsu Chemical Co Choyoseihifukuyakuzaino seizohoho
US4151273A (en) * 1974-10-31 1979-04-24 The Regents Of The University Of California Increasing the absorption rate of insoluble drugs
US4127647A (en) * 1975-04-08 1978-11-28 Meiji Seika Kaisha, Ltd. Process for preparation of stable amorphous macrolide antibiotic solids
JPS51118816A (en) * 1975-04-08 1976-10-19 Meiji Seika Kaisha Ltd A process for stabilizing non-crystalloidal solid
AU508480B2 (en) * 1977-04-13 1980-03-20 Asahi Kasei Kogyo Kabushiki Kaisha Microcrystalline cellulose excipient and pharmaceutical composition containing thesame
GB1579818A (en) * 1977-06-07 1980-11-26 Yamanouchi Pharma Co Ltd Nifedipine-containing solid preparation composition
US4180559A (en) * 1978-01-05 1979-12-25 Richardson-Merrell Inc. Coated 1-(2-chlorodibenzo[b,f]oxepin-10-yl)-4-methylpiperazine compositions
DE2845326C2 (de) * 1978-10-18 1985-05-23 Beiersdorf Ag, 2000 Hamburg Verwendung einer spezifischen mikrodispersen, amorphen, porösen Kieselsäure zur Herstellung von Digoxin enthaltenden Tabletten mit stark beschleunigter Wirkstoff-Freisetzung
DE2847237A1 (de) 1978-10-31 1980-05-14 Bayer Ag Verfahren zur herstellung von 1,4-dihydropyridincarbonsaeuren sowie ihre verwendung als arzneimittel
US4344934A (en) * 1978-11-20 1982-08-17 American Home Products Corporation Therapeutic compositions with enhanced bioavailability
US4269859A (en) * 1979-04-19 1981-05-26 Brown Company Cellulose floc granules and process
CA1146866A (en) * 1979-07-05 1983-05-24 Yamanouchi Pharmaceutical Co. Ltd. Process for the production of sustained release pharmaceutical composition of solid medical material
US4252786A (en) * 1979-11-16 1981-02-24 E. R. Squibb & Sons, Inc. Controlled release tablet

Also Published As

Publication number Publication date
DE3024858C2 (de) 1996-02-29
CH648484A5 (de) 1985-03-29
ES8200557A1 (es) 1981-11-16
US4343789A (en) 1982-08-10
SE448342B (sv) 1987-02-16
US4404183A (en) 1983-09-13
US4673564A (en) 1987-06-16
FR2460667A1 (fr) 1981-01-30
IT8023228A0 (it) 1980-07-03
DE3024858A1 (de) 1981-01-22
GB2053681A (en) 1981-02-11
FR2460667B1 (es) 1983-07-29
IT1132169B (it) 1986-06-25
CA1146866A (en) 1983-05-24
GB2053681B (en) 1984-04-04
SE8004938L (sv) 1981-01-06

Similar Documents

Publication Publication Date Title
ES493152A0 (es) Un procedimiento para la preparacion de una composicion farmaceutica de cesion sostenida de un producto medio solido.
ES497470A0 (es) Un procedimiento para la preparacion de una composicion blanqueadora.
ES490018A0 (es) Un procedimiento para la preparacion de una nueva composi- cion de copolieterester.
ES504905A0 (es) Un procedimiento para la preparacion de una nueva formulacion de bacampicilina.
ES490294A0 (es) Un procedimiento para la preparacion de una composicion blanqueante y limpiadora.
ES503011A0 (es) Un procedimiento para la preparacion de una formulacion por-tadora de farmacos,biodegradable y magneticamente localiza- ble
ES490276A0 (es) Un procedimiento para la preparacion de un copolimero de composicion uniforme.
ES495377A0 (es) Un procedimiento para la preparacion de un producto moldea- do.
ES486067A0 (es) Un procedimiento para la preparacion de un producto deter- gente.
ES476776A0 (es) Un procedimiento para la preparacion de un producto deter- gente desodorante.
ES518879A0 (es) Un procedimiento para la preparacion de una composicion termoplastica cargada.
ES498055A0 (es) Un procedimiento para la preparacion de una piridilanilina
ES507043A0 (es) Un procedimiento para la preparacion de derivados de 2,4-diaminoquinazolina.
ES494435A0 (es) Un procedimiento para la preparacion de nuevos antibioticos de milbecina.
ES503790A0 (es) Un procedimiento para la preparacion de una composicion de derivados del imidazor.
ES496213A0 (es) Un procedimiento para la preparacion de una composicion po- limerica hidroxilada sintetica.
ES508469A0 (es) Un procedimiento para la preparacion de una composicion de poliamida.
ES497825A0 (es) Un procedimiento para la produccion de una composicion de silicona.
ES486069A0 (es) Un procedimiento para la preparacion de un producto deter- gente.
ES506992A0 (es) Un procedimiento para la preparacion de una macroliada.
ES490120A0 (es) Procedimiento para la obtencion de un producto mezclado parala fabricacion de electrodos.
ES484916A0 (es) Un procedimiento para la preparacion de una composicion ter-moplastica.
ES511079A0 (es) Un procedimiento para la preparacion de una n-(2-pirimidinil) piperazinilalquilazaespiroalcanodiona.
ES486068A0 (es) Un procedimiento para la preparacion de un producto deter- gente.
ES504741A0 (es) Un procedimiento para la preparacion de una composicion esporicida de dialdehido-diol.